title: Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.
abstract: OBJECTIVE
  The objective of this study is to analyze the expression and clinical role of integrin-linked kinase (ILK), α-parvin, β-parvin and migfilin in advanced-stage serous ovarian carcinoma.
  
  
  METHODS
  Expression of these 4 proteins was investigated in 205 effusions and in 94 patient-matched solid lesions (33 primary tumors and 61 solid metastases) using immunohistochemistry. Protein expression was analyzed for association with clinicopathologic parameters and survival.
  
  
  RESULTS
  ILK, α-parvin, β-parvin and migfilin were expressed in tumor cells in 53%, 2%, 28% and 53% of effusions and 57%, 20%, 83% and 25% of solid lesions, respectively. Statistical analysis showed significantly higher α-parvin and β-parvin expression in primary carcinomas (p=0.02 and p=0.001, respectively) and solid metastases (p=0.001 and p<0.001, respectively), compared to effusions, with opposite findings for migfilin (p=0.006 and p=0.008 for primary carcinomas and solid metastases, respectively). ILK expression was comparable at all anatomic sites. β-Parvin expression in effusions was associated with better response to chemotherapy at diagnosis (p=0.014), with no other significant association with clinicopathologic parameters or survival. Expression in primary tumors and solid metastases was similarly unrelated to clinicopathologic parameters or survival.
  
  
  CONCLUSIONS
  This study provides further evidence to our previous observations that the adhesion profile of ovarian serous carcinoma cells in effusions differs from their counterparts in primary carcinomas and solid metastases. β-Parvin may be a novel marker of chemoresponse in metastatic ovarian carcinoma.
authors.affiliation: Division of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N-0424 Oslo, Norway. bend@medisin.uio.no
authors.forename: Ben
authors.initials: B
authors.lastname: Davidson
authors.forename: Arild
authors.initials: A
authors.lastname: Holth
authors.forename: Mai T P
authors.initials: MT
authors.lastname: Nguyen
authors.forename: Claes G
authors.initials: CG
authors.lastname: Tropé
authors.forename: Chuanyue
authors.initials: C
authors.lastname: Wu
mesh_terms: D000185:Actinin / Q000096:biosynthesis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001202:Ascitic Fluid / Q000378:metabolism* / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000096:biosynthesis*; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000473:pathology; D003598:Cytoskeletal Proteins / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008840:Microfilament Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D046888:Tissue Array Analysis; D000096985:Calponins
chemical_list: D000185:Actinin; D015815:Cell Adhesion Molecules; D003598:Cytoskeletal Proteins; D008840:Microfilament Proteins; C473794:FBLIM1 protein, human; C486590:PARVA protein, human; D000096985:Calponins; C486591:PARVB protein, human